Compare · CGC vs MNMD
CGC vs MNMD
Side-by-side comparison of Canopy Growth Corporation (CGC) and Mind Medicine (MindMed) Inc. (MNMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CGC and MNMD operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- CGC is the larger of the two at $2.86B, about 6.5x MNMD ($438.1M).
- Over the past year, CGC is down 24.9% and MNMD is up 55.7% - MNMD leads by 80.6 points.
- CGC has hit the wire 6 times in the past 4 weeks while MNMD has been quiet.
- CGC has more recent analyst coverage (19 ratings vs 16 for MNMD).
- Company
- Canopy Growth Corporation
- Mind Medicine (MindMed) Inc.
- Price
- $0.93+0.03%
- $15.01+0.84%
- Market cap
- $2.86B
- $438.1M
- 1M return
- -3.44%
- +19.56%
- 1Y return
- -24.94%
- +55.65%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 6
- 0
- Recent ratings
- 19
- 16
Canopy Growth Corporation
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flowers, oils and concentrates, and softgel capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel, DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Bean & Bud brands. The company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada and NHL Alumni Association to examine the efficacy of CBD-based therapies as part of the mitigation of persistent post-concussion symptoms. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.
Latest CGC
- Canopy Growth Announces Participation at Upcoming Canaccord Genuity Growth Conference
- SEC Form PRE 14A filed by Canopy Growth Corporation
- Director Bayern Joseph sold $2,953 worth of shares (3,197 units at $0.92), decreasing direct ownership by 2% to 145,127 units (SEC Form 4) (withholding tax)
- Director Yanofsky Theresa sold $13,905 worth of shares (15,054 units at $0.92), decreasing direct ownership by 9% to 146,415 units (SEC Form 4) (withholding obligation)
- Director Atkins M Shan sold $2,953 worth of shares (3,197 units at $0.92), decreasing direct ownership by 2% to 146,517 units (SEC Form 4) to cover taxes
- Director Lazzarato David Angelo sold $20,944 worth of shares (22,674 units at $0.92), decreasing direct ownership by 10% to 211,859 units (SEC Form 4) to cover withholding tax
- Director Atkins M Shan was granted 108,324 shares, increasing direct ownership by 262% to 149,714 units (SEC Form 4)
- Director Lazzarato David Angelo was granted 162,485 shares, increasing direct ownership by 226% to 234,533 units (SEC Form 4)
- Director Bayern Joseph was granted 108,324 shares, increasing direct ownership by 271% to 148,324 units (SEC Form 4)
- Director Yanofsky Theresa was granted 108,324 shares, increasing direct ownership by 204% to 161,469 units (SEC Form 4)
Latest MNMD
- Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- Chief Legal Officer Sullivan Mark sold $148,244 worth of shares (11,276 units at $13.15), decreasing direct ownership by 4% to 282,576 units (SEC Form 4)
- Chief Executive Officer Barrow Robert sold $339,072 worth of shares (25,791 units at $13.15), decreasing direct ownership by 3% to 778,477 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel sold $73,623 worth of shares (5,600 units at $13.15), decreasing direct ownership by 1% to 425,025 units (SEC Form 4)
- SEC Form 144 filed by Mind Medicine (MindMed) Inc.
- MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference
- MindMed Announces New Employee Inducement Grant
- MindMed Announces New Employee Inducement Grants
- SEC Form 10-Q filed by Mind Medicine (MindMed) Inc.
- Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits